Onconetix, Inc.
Onconetix, Inc. (ONCO): 3 pipeline candidates · 1 upcoming catalyst · ~6 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
5.5 months
D/E 0.26 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~805d
3 buys · 3 sells (180d)
A transparent, data-derived signal for Onconetix, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.0M
Cash
$3.7M
Quarterly Burn
$2.1M
Runway
5.5 mo
Revenue
$21K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| entadfi | Approved |
| gotistobart | Phase 3 |
| proclarix | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$20K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 11,854 | $18K |
| citigroup inc | 1,717 | $3K |
Frequently asked questions
How many drug candidates are in Onconetix, Inc.'s pipeline?
Onconetix, Inc. (ONCO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Onconetix, Inc.'s lead drug candidate?
Onconetix, Inc.'s most advanced tracked candidate is entadfi (Approved) for BPH (benign prostatic hyperplasia).
What is Onconetix, Inc.'s next catalyst?
Onconetix, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung C" — expected August 31, 2028.
What is Onconetix, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Onconetix, Inc. has approximately 5.5 months of cash runway.
What is Onconetix, Inc.'s market capitalization?
Onconetix, Inc.'s market capitalization is approximately $4.0M.
Get the full picture on Onconetix, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.